Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia
- 1 February 2016
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (4), 300-302
- https://doi.org/10.1200/jco.2015.64.8907
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?Journal of Clinical Oncology, 2016
- One million haemopoietic stem-cell transplants: a retrospective observational studyThe Lancet Haematology, 2015
- The Leukemias: A Half-Century of DiscoveryJournal of Clinical Oncology, 2014
- A 50-Year Journey to Cure Childhood Acute Lymphoblastic LeukemiaSeminars in Hematology, 2013
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaThe New England Journal of Medicine, 2013
- Economics of hematopoietic cell transplantationBlood, 2012
- Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large National Private Claims DatabaseBone Marrow Transplantation, 2012
- Modern Therapy of Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2011
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003